Tumor and autoimmune disease seriously endanger human health. Our primary mission is to develop novel and highly-effective drugs to satisfy the unmet medical needs of patients.
To ensure that our goal is thoroughly and smoothly achieved, we have designed and established the protein homeostasis technology and computer aided drug design (CADD) platform, which facilitate the validation of protein targets that are highly related to the progression and recurrence of diseases, and eventually accelerate the discovery of new drug molecules.
As a high-tech pharmaceutical company with originally innovative capability, we are dedicated to develop novel drugs against undruggable targets through taking advantage of Molecular Glue and Protac technology, which in turn provides effective solutions for original innovative drugs.
Based on the molecular simulation theory of quantum and molecular mechanics, computer aided drug design (CADD) is capable of predicting the interaction between drugs and target molecules, screening and designing the methodology for optimizing lead compounds through simulating, calculating or model learning. We have a professional and energetic team with extensive practical experience in CADD, and are able to implement structure-based or ligand-based pharmaceutical designing strategies, and predict physicochemical and DMPK properties with the aim to improve the efficiency of R&D of innovative drugs.
| Program | Modality | Indication | Discovery | Preclinical | Early phase development | Late phase development |
| HP-001 | Molecular glue | Hematologic Malignancies |
|
|||
| HP-002 | Protac | Hematologic Malignancies |
|
|||
| CY002 | Molecular glue | Solid tumor |
|
|||
| CY004 | Protac | Solid tumor |
|
|||
| CY006 | DAC | Tumor/Autoimmune |
|
|||
| CY007 | Molecular glue | Autoimmune |
|
|||
